NTC grants license and distribution rights to Santen for its fixed combination dexamethasone with levofloxacin, a novel eye drop treatment for ocular inflammation.
NTC Srl (hereinafter NTC), an Italian pharmaceutical company with significant expertise in research and development, announces today a commercial partnership with Santen Pharmaceutical Co., Ltd. (hereinafter Santen), a global leading pharmaceutical player in ophthalmology. NTC granted to Santen license and distribution rights of one of its research and development products, meant to address unmet medical needs in the treatment of post cataract surgery. This new therapeutic solution is a fixed combination of dexamethasone with levofloxacin: it is the first product combining a quinolone antibiotic with an anti-inflammatory steroid in eye drops in Europe. The product will be supported with data arising from one of the largest clinical programs ever conducted in Europe in ophthalmology, consisting of nearly 1000 patients enrolled in controlled clinical studies.
“Partnering with a leading company in ophthalmology like Santen in EMEA,” – says Riccardo Carbucicchio, President and CEO of NTC, – “is an honor to us. It also represents to NTC a confirmation about the value of its development efforts in the ophthalmic area.
Running an international research and development program is a great opportunity for an Italian based company like us, willing to invest in R&D in ophthalmology to offer to the scientific community better products with tangible novel therapeutic evidences, aimed finally to unleash improved therapeutic offering to patients.
The ability to bring Italian innovation internationally thanks to partnership with global leading players like Santen,” refers Carbucicchio, “is a great achievement for NTC. The fixed combination dexamethasone + levofloxacin in eye drops aims to represent an effective therapeutic solution and at the same time to use the antibiotic therapy only for the limited time needed. NTC is engaged in a large development and clinical program on several products, meant, in particular, to reduce the antibiotic exposure to patients and to improve compliance for a better therapeutic outcome in ophthalmology”.
NTC keeps pursuing its path in developing R&D projects with international potential in the therapeutic areas where NTC is engaged, in particular in ophthalmology, aiming at partnering them with leading international players.
About NTC Srl
NTC is a pharmaceutical company headquartered in Milan - Italy, with distributors and partners in more than 70 countries in the world, engaged in research, development, registration and commercialization of drugs, medical devices and food supplements in ophthalmology, but also in other therapeutic areas like pediatrics and gastro-metabolism. NTC offers to its partners, currently more than 200 companies, innovative pharmaceutical products with high quality standards. For more details, please see NTC's website (http://www.ntcpharma.com).
About Santen Pharmaceutical Co Ltd
As a specialty company dedicated to the ophthalmic field, Santen carries out research, development, sales, and marketing of pharmaceuticals. Santen is the market leader in Japan for prescription ophthalmic pharmaceuticals and sells products in approximately 60 countries. As a leading company in the field of ophthalmology, Santen aims to contribute to society by supplying valuable products and services to satisfy unmet medical needs. For more details, please see Santen's website (www.santen.com).
M. Claudia Nacci